rawfin.tv
Novo Nordisk Shares Plunge 9% on Failed Heart Medicine Trial
Breaking Newsstocks🔴 Score 9AI Generated

Novo Nordisk Shares Plunge 9% on Failed Heart Medicine Trial

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Novo Nordisk A/S shares plummeted 9% after its experimental heart medicine, ziltivekimab, failed to achieve a statistically significant reduction in major cardiovascular events during trials. This setback impacts the company's drug pipeline.

NVODrug TrialBiopharmaStock DropClinical Trials

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks